EcoDrugPlus

Cyclin-Dependent Kinase 5-Like

Ensembl ID : ENSNBRG00000011455
Gene Symbol: LOC102790139
3 Cross references
169 Possible Orthologues:

Cyclin-Dependent Kinase 6-Like

Ensembl ID : ENSNBRG00000008020
Gene Symbol: LOC102782226
3 Cross references
200 Possible Orthologues:

Cyclin-Dependent Kinase 7-Like

Ensembl ID : ENSNBRG00000003836
Gene Symbol: LOC102781317
3 Cross references
218 Possible Orthologues:

Cyclin-Dependent Kinase 9-Like

Ensembl ID : ENSNBRG00000004264
Gene Symbol: LOC102784396
3 Cross references
207 Possible Orthologues:

Cysteinyl Leukotriene Receptor 1-Like

Ensembl ID : ENSNBRG00000020287
Gene Symbol: LOC102786010
3 Cross references
172 Possible Orthologues:

Cystic Fibrosis Transmembrane Conductance Regulator-Like

Ensembl ID : ENSNBRG00000012871
Gene Symbol: LOC102784864
3 Cross references
214 Possible Orthologues:

Cytidine Deaminase-Like

Ensembl ID : ENSNBRG00000013678
Gene Symbol: LOC102780564
3 Cross references
200 Possible Orthologues:

Cytochrome P450 26a1-Like

Ensembl ID : ENSNBRG00000010359
Gene Symbol: LOC102790555
3 Cross references
193 Possible Orthologues:

Cytochrome P450 26a1-Like

Ensembl ID : ENSNBRG00000023492
Gene Symbol: LOC102797675
3 Cross references
193 Possible Orthologues:

Cytochrome P450 3a40-Like

Ensembl ID : ENSNBRG00000012050
Gene Symbol: LOC102796416
2 Cross references
520 Possible Orthologues:

Cytochrome P450 3a40-Like

Ensembl ID : ENSNBRG00000012065
Gene Symbol: LOC102796123
2 Cross references
518 Possible Orthologues:

Cytochrome P450 3a40-Like

Ensembl ID : ENSNBRG00000009035
Gene Symbol: LOC102794533
3 Cross references
474 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).